case_images: PMC11007123_01
case_images: Treatment flowchart: PLD, pegylated liposomal doxorubicin; CTX, cyclophosphamide; Lipusu, paclitaxel liposome; CAPE, capecitabine; NVB, vinorelbine; PD, disease progression.
case_images: fonc-14-1328844-g001.jpg
case_images: PMC11007123_01_fonc-14-1328844-g001.jpg
case_images: f1
case_images: October 2018 ( Figure 1 ). On June 17, 2019, this patient received left breast-conserving surgery and lymph node dissection in our hospital.
case_images: Pathological findings for the patient. (A) Hematoxylin and eosin staining of the tumor, diagnosed as invasive ductal carcinoma, H&E, x100. (B) Immunohistochemistry of primary tumor, H&E, x100. (C) Immunohistochemistry of lung metastasis, H&E, x100. (D) Immunohistochemistry of PD-L1 of the lung metastasis, H&E, x100.
case_images: fonc-14-1328844-g002.jpg
case_images: PMC11007123_01_fonc-14-1328844-g002.jpg
case_images: f2
case_images: II infiltrating ductal carcinoma, tumor size of 1 * 0.8 * 0.8 cm, and axillary lymph node metastasis (2/9). Immunohistochemical examination results showed ER (50%+), PR (30%+), HER2 (-), and Ki-67 (40%+) ( Figures 2A, B ). PD-L1 combined positive score (CPS) was 3 points ( Figures 2C, D ).
case_images: The response of lung metastases to immunotherapy combined with chemotherapy. (A) Before combination therapy. (B) After two cycles of treatment. (C) After four cycles of treatment.
case_images: fonc-14-1328844-g003.jpg
case_images: PMC11007123_01_fonc-14-1328844-g003.jpg
case_images: f3
case_images: From September 2021 to January 2022, the patient was given "capecitabine plus vinorelbine" treatment and then received capecitabine or vinorelbine maintenance therapy ( Figure 3 ). The relief rate was more than 95% ( Figures 3 ,  4 ).
case_images: The response of liver metastases to immunotherapy combined with chemotherapy. (A) Before combination therapy. (B) After two cycles of treatment. (C) After four cycles of treatment.
case_images: fonc-14-1328844-g004.jpg
case_images: PMC11007123_01_fonc-14-1328844-g004.jpg
case_images: f4
case_images: The relief rate was more than 95% ( Figures 3 ,  4 ).
case_images: Trend chart of changes in tumor biomarkers before and after immunotherapy. (A) CA15-3, carbohydrate antigen 15-3. (B) CA19-9, carbohydrate antigen 19-9. (C) CA125, carbohydrate antigen 125. (D) CEA, carcinoembryonic antigen.
case_images: fonc-14-1328844-g005.jpg
case_images: PMC11007123_01_fonc-14-1328844-g005.jpg
case_images: f5
case_images: Both carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) increased at first and then decreased ( Figure 5 ).